A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection (SMR-2591)

AlgiPharma

Status and phase

Completed

Phase 2

Conditions

Burkholderia Infection

Cystic Fibrosis

Treatments

Drug: Placebo

Drug: Alginate oligosaccharide

Study type

Interventional

Funder types

Industry

Identifiers

NCT02453789

SMR-2591

Details and patient eligibility

About

The purpose of the study is to assess the efficacy of Alginate oligosaccharide (OligoG) dry powder for inhalation in cystic fibrosis (CF) patients with a Burkholderia spp. infection.

Full description

Primary objective:

To explore the efficacy of inhaled OligoG in reducing the microbial burden of Burkholderia spp. as measured in expectorated sputum samples.

Secondary objectives:

To explore the effect of inhaled OligoG on various efficacy variables such as lung function, Quality-of-Life, rheology and other microbiological outcome measures.

To evaluate the safety, tolerability and subject compliance with treatment The study will also evaluate the effect of inhaled OligoG on various efficacy variables such as lung function, Quality-of-Life, rheology and other microbiological outcome measures, and evaluate the safety and patient compliance with treatment.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female with a confirmed diagnosis of cystic fibrosis defined by:
- Clinical features consistent with the diagnosis of CF; AND
- Sweat chloride ≥60 mmol/L by pilocarpine iontophoresis; OR
- Genotypic confirmation of CFTR mutation
Aged 18 years or older
Ability to provide sputum samples for microbiological evaluation throughout the study either spontaneously or induced.
Chronic colonization with Burkholderia spp. defined as at least two positive microbiological cultures in expectorated sputum within the last 12 months from Visit 1.
Use of inhaled aztreonam three times daily in a 4 weeks on/off cycle treatment regimen or a continuous intake regimen for at least 4 weeks before screening visit. For on/off cycles, screening visit should take place in the off phase. Randomization visit should take place the first day "on" to harmonize the aztreonam inhalation period with the IMP intake period.
Willingness to stop treatment with other inhaled antibiotics.
At Screening no clinical or laboratory findings suggestive of significant pulmonary illness, other than CF, which in the opinion of the investigator would preclude participation in the study.
FEV1 greater than 25% of the predicted normal value following adjustment for age, gender, and height according to the Global Lung Initiative
Female subjects of child bearing potential and male subjects participating in the study who are sexually active must use acceptable contraception. Female subjects documented as being of non-child-bearing potential are exempt from the contraceptive requirements.
Provision of written informed consent.

Exclusion criteria

Changes in underlying therapy within the 14 days prior to Day 0. Subjects must be willing to remain on the same underlying stable therapy regimens for the duration of the study until the final follow-up visit at Day 98.
Changes in physiotherapy technique or schedule within 14 days prior to Day 0.
Prohibited medications within 7 days prior to Day 0. Concomitant administration of inhaled mannitol or hypertonic saline within 7 days prior to Day 0.
Concomitant use of inhaled antibiotics other than aztreonam.
Pulmonary exacerbation within 28 days of Screening.
Lactose intolerance/milk allergy.
On-going acute illness. Subjects must not have needed an outpatient visit, hospitalization or required any change in therapy for other pulmonary disease between Screening and Day 0.
History of, or planned organ transplantation.
Active allergic bronchopulmonary aspergillosis (ABPA) in the last 12 months prior to Screening, defined as having received treatment for ABPA.
Inability or unwillingness to provide sputum samples for microbiological evaluation throughout the study either spontaneously or induced by means of using inhaled hypertonic saline.
Clinically significant abnormal findings on haematology or clinical chemistry. In addition, any value ≥ 3 x the upper limit of normal will exclude the subject from participating in the study.
Subjects unable to perform pulmonary function tests according to the ATS/ERS criteria.
Pregnant or breast-feeding women. A negative urine pregnancy test must be demonstrated in females of child-bearing potential at Screening.
Subjects who have participated in any interventional clinical trial within the 28 days prior to Day 0.
Subjects with documented or suspected, clinically significant, alcohol or drug abuse, as determined by the Investigator.
Current malignant disease (with the exception of basal cell carcinoma; BCC).
Any serious or active medical or psychiatric illness, which in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
Patients not willing/able to follow the study instructions.
Resistance to aztreonam, or intolerance to aztreonam or any of its excipients.